[Toward novel therapeutic strategies: Targeting the extracellular matrix to broaden the therapeutic window].

Authors

S Kunz, L Seguin, C C Féral

Published in

Revue des maladies respiratoires. Aug 11, 2026. Epub Aug 11, 2026.

Abstract

Lung cancer is a major public health concern, ranking as the third most common cancer in women and the second in men, entailing significant mortality. Immune checkpoint inhibitors (ICIs, anti-PD-1/PD-L1) have transformed the treatment of advanced lung adenocarcinoma, thereby prolonging survival. However, many patients develop therapeutic resistance. Increased stiffness of the extracellular matrix (ECM) of the tumor represents a critical obstacle to immunotherapy efficacy, limiting lymphocyte infiltration. Modulation through integrins of the mechanical properties of the ECM could restore immune accessibility and potentiate ICIs, opening new therapeutic perspectives for treatment of advanced lung cancer.

PMID:
42580946
Bibliographic data and abstract were imported from PubMed on 12 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.